When Mylan announced early last month that it had reached a preliminary $465 million settlement with the U.S. Justice Department over Medicaid rebates for its EpiPen, many were surprised at how swiftly the company had been able to resolve the matter.

After all, questions about whether Mylan was shortchanging the Medicaid program by misclassifying the EpiPen emergency allergy shot as a generic instead of a brand-name drug had only been in the public spotlight since August.

But, according to a filing with the Securities and Exchange Commission on Wednesday, the Justice Department has been investigating the issue for at least the last two years.

Mylan received a subpoena from the department seeking information about whether the EpiPen auto-injector was properly classified under the Medicaid rebate program back in November 2014, Mylan disclosed this week in its quarterly financial report with the SEC.

Advertise with us

The drug maker received “additional inquiries” about the issue from lawmakers and other state and federal agencies in August, the filing said.

Mylan announced the proposed $465 million settlement with the Justice Department on Oct. 7. The deal, which the company has said is still being finalized, does not include an admission of wrongdoing.

Wednesday’s filing was the first time Mylan disclosed that it had received the subpoena.

Experts said Thursday it was unclear whether the company should have revealed it earlier.

“Disclosure really is a judgement call,” said securities attorney Irwin Kishner, a partner with Herrick, Feinstein in New York.

Advertise with us

“Public companies must report things that are material” in the context of their business, he said.

“Not every subpoena rises to the level of materiality. The question is, at what point did they realize it was going to be a material” item?

Mylan, which has its operations base in Cecil, did not respond to emails Thursday seeking comment.

“Disclosure is an art, not a science. That’s the problem with it,” said Charles Elson, director of the Center for Corporate Governance at the University of Delaware.

“The key is you have to disclose material facts,” he said. “Why they didn’t disclose it, I don’t know. That’s something they should explain.”

Advertise with us

The $465 million settlement has come under fire from legislators as being too soft on Mylan.

The U.S. Senate Judiciary Committee has set a hearing for Nov. 30 to scrutinize the deal.

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.